FDA fiddles with legislated deadline schedule
Pharmacies and some health systems are getting another breather from FDA: the requirement to have product tracing information (at the lot level) on hand was supposed to go into effect on July 1, which was pushed back to November 1, and now is being pushed to March 1, 2016.
Many of the details of the Drug Supply Chain Security Act (DSCSA) were written into the law itself, but FDA has some degree of “enforcement discretion” even with mandated deadlines. Manufacturers were to begin collecting and then passing tracing data on Jan 1 of this year, but FDA pushed that off to May 1. Getting two postponements certainly indicates a less-than-enthusiastic response to the law, but as there are subsequent deadlines for other traceability criteria hitting in 2017 and beyond, the pharmacy sector will be compelled to get up to speed, eventually. The postponement is also an acknowledgement that FDA simply can’t shut down dispensing activity because of noncompliance; the effects on public health would be severe.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.